

GUIDELINE AND POSITION STATEMENTS

1. Armenian SH, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol*. 2017 Mar 10; 35(8):893-911. PMID 27918725
2. Bloom MW, et al. Cancer therapy-related cardiac dysfunction and heart failure: Part 1: definitions, pathophysiology, risk factors, and imaging. *Circ Heart Fail*. 2016; 9(1):e002661. PMID: 26747861
3. Campi U, et al. Cardio-Oncology: vascular and metabolic perspectives: A Scientific Statement from the American Heart Association. *Circulation*. 2019 Mar 26; 139(13):e579-e602. PMID: 30786722
4. Curigliano G, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents, and radiotherapy: ESMO Clinical Practice Guidelines. *Ann Oncol*. 2012 Oct; 23 Suppl 7:vii155-66. PMID: 22997448
5. Gilchrist SC, et al. Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association. *Circulation*. 2019 May 21; 139(21):e997-e1012. PMID: 30955352
6. Hamo CE, et al. Cancer therapy-related cardiac dysfunction and heart failure: Part 2: prevention, treatment, guidelines, and future directions. *Circ Heart Fail*. 2016 Feb; 9(2):e002843. PMID: 26839395
7. Ilescu C, et al. SCAI expert consensus: evaluation, management, and special considerations of cardio-oncology patients in the cardiac catheterization laboratory (Endorsed by the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencionista). *Catheter Cardiovasc Interv*. 2016 Apr; 87(5):E202-223. PMID: 26756277
8. Maurer MS, et al. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. *Circ Heart Fail*. 2019 Sep; 12(9):e006075. PMID: 31480867
9. Plana JC, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *J Am Soc Echocardiogr*. 2014 Sep; 27(9):911-939. PMID: 25172399
10. Zamorano JL, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). *Eur Heart J*. 2016 Sept 21; 37(36):2768-2801. PMID: 27567406

IMMUNE CHECKPOINT INHIBITORS

1. Ball S, et al. Cardiovascular toxicities of immune checkpoint inhibitors: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019 Oct 1; 74(13):1714-1727. PMID: 31558256

2. Bonaca MP, et al. Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology. *Circulation*. 2019 Jul 2; 140(2):80-91. PMID: 31390169
3. Davis EJ, et al. Hematologic complications of immune checkpoint inhibitors. *Oncologist*. 2019 May; 24(5):584-588. PMID: 30819785
4. Lyon AR, et al. Immune checkpoint inhibitors and cardiovascular toxicity. *Lancet Oncol*. 2018 Sep; 19(9):e447-e458. PMID: 30191849
5. Mahmood SS, et al. Myocarditis in patients treated with immune checkpoint inhibitors. *J Am Coll Cardiol*. 2018 Apr 24; 71(16):1755-1764. PMID: 29567210
6. Moslehi JJ, et al. Fulminant myocarditis: evolving diagnosis, evolving biology, evolving prognosis. *J Am Coll Cardiol*. 2019 Jul 23; 74(3):312-314. PMID: 31319913
7. Puzanov I, et al. Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. *J Immunother Cancer*. 2017 Nov 21;5(1):95. PMID: 29162153

AMYLOIDOSIS AND MULTIPLE MYELOMA AND THEIR THERAPEUTICS

1. Barrett CD, et al. A changing landscape of mortality for systemic light chain amyloidosis. *JACC Heart Fail*. 2019 Oct 5. pii: S2213-1779(19)30593-1. PMID: 31606365
2. Chari A, et al. Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trials. *Blood Adv*. 2018 Jul 10; 2(13):1633-1644. PMID: 29991494
3. Cornell RF, et al. Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma. *J Clin Oncol*. 2019 Aug 1; 37(22):1946-1955. PMID: 31188726
4. Falk RH, et al. AL (light-chain) cardiac amyloidosis: a review of diagnosis and therapy. *J Am Coll Cardiol*. 2016 Sep 20; 68(12):1323-1341. PMID: 27634125
5. Fradley MG, et al. Recurrent cardiotoxicity potentiated by the interaction of proteasome inhibitor and immunomodulatory therapy for the treatment of multiple myeloma. *Br J Haematol*. 2018 Jan; 180(2):217-275. PMID: 29048105
6. Judge DP, et al. Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. *J Am Coll Cardiol*. 2019 Jul 23; 74(3):285-295. PMID: 30885685
7. Li W, et al. Cardiovascular and thrombotic complications of novel multiple myeloma therapies: a review. *JAMA Oncol*. 2017 Jul 1; 3(7):980-988. PMID: 27632640
8. Li W, et al. Cardiovascular complications of novel multiple myeloma treatments. *Circulation*. 2016 Mar 1; 133(9):908-912. PMID: 26927008

9. Maurer MS, et al. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes. *Circ Heart Fail*. 2015 May; 8(3):519-526.
10. Maurer MS, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. *N Engl J Med*. 2018 Sep 13; 379(11):1007-1016. PMID: 30145929
11. Witteles RM, et al. Screening for transthyretin amyloid cardiomyopathy in everyday practice. *JACC Heart Fail*. 2019 Aug; 7(8):709-716. PMID: 31302046
12. Zhang KW, et al. Emerging therapeutics for the treatment of light chain and transthyretin amyloidosis. *JACC Basic Transl Sci*. 2019 Jun 24; 4(3):438-448. PMID: 31312767

BREAST CANCER

1. Curigliano G, et al. Prevention, monitoring, and management of cardiac dysfunction in patients with metastatic breast cancer. *Oncologist*. 2019 May 7. pii: theoncologist.2018-0773. PMID: 31064888
2. Ewer MS, et al. Reversibility of trastuzumab-related cardiotoxicity: new insights based on clinical course and response to medical treatment. *J Clin Oncol*. 2005 Nov 1; 23(31):7820-7826. PMID: 16258084
3. Matthews A, et al. Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. *BMJ*. 2018 Oct 8;363:k3845. PMID: 30297439

PROSTATE CANCER

1. Bhatia N, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. *Circulation*. 2016 Feb 2; 133(5):537-541. PMID: 26831435

GENERAL TOPICS IN CARDIO-ONCOLOGY

1. Armenian SH, et al. Cardiovascular disease in survivors of childhood cancer: insights into epidemiology, pathophysiology, and prevention. *J Clin Oncol*. 2018 Jul 20; 36(21):2135-2144. PMID: 29874141
2. Armenian SH, et al. Prevalence of anthracycline-related cardiac dysfunction in long-term survivors of adult-onset lymphoma. *Cancer*. 2018 Feb 15; 124(4):850-857. PMID: 29112235
3. Armstrong GT, et al. Modifiable risk factors and major cardiac events among adult survivors of childhood cancer. *J Clin Oncol*. 2013 Oct 10; 31(29):3673-3680. PMID: 24002505

4. Hayek SS, et al. Preparing the cardiovascular workforce to care for oncology patients: JACC Review Topic of the Week. *J Am Coll Cardiol*. 2019 May 7; 73(17):2226-2235. PMID: 31047011
5. Jones DN, et al. Frequency of transition from stage A to stage B heart failure after initiating potentially cardiotoxic chemotherapy. *JACC Heart Fail*. 2018 Dec; 6(12):1023-1032. PMID: 30414819
6. Scott JM, et al. Association of exercise with mortality in adult survivors of childhood cancer. *JAMA Oncol*. 2018 Oct 1; 4(10):1352-1358. PMID: 29862412

VASCULAR TOXICITIES

1. Herrmann J. Common vascular toxicities of cancer therapies. *Cardiol Clin*. 2019 Nov; 37(4):365-384. PMID: 31587779.
2. Hermann J, et al. Vascular toxicities of cancer therapies: the old and the new—an evolving avenue. *Circulation*. 2016 Mar 29; 133(13):1272-1289. PMID: 27022039
3. Li W, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. *J Am Coll Cardiol*. 2015 Sep 8;66(10):1160-1178. PMID: 26337996
4. Touyz RM, et al. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events. *J Am Soc Hypertens*. 2018 Jun; 12(6):409-425. PMID: 29703600

VTE PROPHYLAXIS AND TREATMENT

1. Carney BJ, et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. *J Thromb Haemost*. 2019 Jan; 17(1):72-76. PMID: 30450803
2. Carrier M, et al. Apixaban to prevent venous thromboembolism in patients with cancer. *N Engl J Med*. 2019 Feb 21; 380(8):711-719. PMID: 30511879
3. Cornell RF, et al. Apixaban for primary prevention of venous thromboembolism in patients with multiple myeloma receiving immunomodulatory therapy. *Front Oncol*. 2019 Feb 26; 9:45. PMID: 30873378
4. Key NS, et al. Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO Clinical Practice Guideline Update. *J Clin Oncol*. 2019 Aug 5;JCO1901461. PMID: 31381464
5. Khorana AA, et al. Development and validation of a predictive model for chemotherapy-associated thrombosis. *Blood*. 2008 May 15; 111(10):4902-4907. PMID: 18216292
6. Khorana AA, et al. Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. *N Engl J Med*. 2019 Feb 21; 380(8):720-728. PMID: 30786186

7. Melloni C, et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. *Am J Med.* 2017 Dec; 130(12):1440-1448. PMID: 28739198
8. Mosarla RC, et al. Anticoagulation strategies in patients with cancer: JACC Review Topic of the Week. *J Am Coll Cardiol.* 2019 Mar 26; 73(11):1336-1349. PMID: 30898209
9. Rakob GE, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. *N Engl J Med.* 2018 Feb 15; 378(7):615-624. PMID: 29231094
10. Young AM, et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). *J Clin Oncol.* 2018 Jul 10; 36(20):2017-2023. PMID: 29746227

BIOMARKERS

1. Cardinale D, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. *J Am Coll Cardiol.* 2000 Aug; 36(2):517-522. PMID: 10933366
2. Cardinale D, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. *Circulation.* 2004 Jun 8; 109(22):2749-2754. PMID: 15148277
3. Cardinale D, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. *J Clin Oncol.* 2010 Sep 1; 28(25):3910-3916. PMID: 20679614

ANTHRACYCLINES

1. Cardinale D, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. *J Am Coll Cardiol.* 2010 Jan 19; 55(3):213-220. PMID: 20117401
2. Cardinale D, et al. Anthracycline-induced cardiotoxicity: A multicenter randomized trial comparing two strategies for guiding prevention with enalapril: The International CardioOncology Society-one trial. *Eur J Cancer.* 2018 May; 94:126-137. PMID: 29567630
3. Cardinale D, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. *Circulation.* 2015 Jun 2; 131(22):1981-1988. PMID: 25948538
4. Cardinale D, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. *Circulation.* 2006 Dec 5; 114(23):2474-2481. PMID: 17101852

IBRUTINIB

1. Brown JR, et al. Incidence of and risk factors for major hemorrhage in patients treated with ibrutinib: an integrated analysis. *Br J Haematol.* 2019 Feb; 184(4):558-569. PMID: 30506764

2. Ganatra S, et al. Ibrutinib-associated atrial fibrillation. *JACC Clin Electrophysiol.* 2018 Dec; 4(12):1491-1500. PMID: 30573111
3. Salem JE, et al. Cardiovascular toxicities associated with ibrutinib. *J Am Coll Cardiol.* 2019 Oct 1; 74(13):1667-1678. PMID: 31558250

CLONAL HEMATOPOIESIS

1. Jaiswal S, et al. Clonal hematopoiesis and risk of atherosclerotic cardiovascular disease. *N Engl J Med.* 2017 Jul 13; 377(2):111-121. PMID: 28636844
2. Libby P, et al. Clonal hematopoiesis: crossroads of aging, cardiovascular disease, and cancer: JACC Review Topic of the Week. *J Am Coll Cardiol.* 2019 Jul 30; 74(4):567-577. PMID: 31345432

IMAGING

1. Armstrong GT, et al. Comprehensive echocardiographic detection of treatment-related cardiac dysfunction in adult survivors of childhood cancer: results from the St. Jude Lifetime Cohort Study. *J Am Coll Cardiol.* 2015 Jun 16; 65(23):2511-2522. PMID: 26065990
2. Jordan JH, et al. Cardiovascular magnetic resonance in the oncology patient. *JACC Cardiovasc Imaging.* 2018 Aug; 11(8):1150-1172. PMID: 30092971
3. Lancellotti P, et al. Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. *J Am Soc Echocardiogr.* 2013 Sep; 26(9):1013-1032. PMID: 23998694
4. Plana JC, et al. Multi-modality imaging in the assessment of cardiovascular toxicity in the cancer patient. *JACC Cardiovasc Imaging.* 2018 Aug; 11(8):1173-1186. PMID: 30092972
5. Thavendiranathan P, et al. Risk-imaging mismatch in cardiac imaging practices for women receiving systemic therapy for early-stage breast cancer: a population-based cohort study. *J Clin Oncol.* 2018 Oct 20; 36(30):2980-2987. PMID: 29791284
6. Walker J, et al. Role of three-dimensional echocardiography in breast cancer: comparison with two-dimensional echocardiography, multiple-gated acquisition scans, and cardiac magnetic resonance imaging. *J Clin Oncol.* 2010 Jul 20; 28(21):3429-3436. PMID: 20530277
7. Zhang KW, et al. Abnormalities in 3-dimensional left ventricular mechanics with anthracycline chemotherapy are associated with systolic and diastolic dysfunction. *JACC Cardiovasc Imaging.* 2018 Aug; 11(8):1059-1068. PMID: 29550306

RADIATION THERAPY

1. Darby SC, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. *N Engl J Med*. 2013 Mar 14; 368(11):987-998. PMID: 23484825
2. Groarke JD, et al. Cardiovascular complications of radiation therapy for thoracic malignancies: the role for non-invasive imaging for detection of cardiovascular disease. *Eur Heart J*. 2014 Mar; 35(10):612-623. PMID: 23666251

HEMATOPOIETIC STEM CELL TRANSPLANTATION

1. Armenian SH, et al. Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease. *Blood*. 2012 Nov 29; 120(23):4505-4512. PMID: 23034279
2. Griffith ML, Savani BN, Boord JB. Dyslipidemia after allogeneic hematopoietic stem cell transplantation: evaluation and management. *Blood*. 2010 Aug 26; 116(8):1197-1204. PMID: 20439623
3. Leger KJ, et al. Lifestyle factors and subsequent ischemia heart disease risk after hematopoietic cell transplantation. *Cancer*. 2018 Apr 1; 124(7):1507-1515. PMID: 29315507
4. Tichelli A, et al. Premature cardiovascular disease after allogeneic hematopoietic stem-cell transplantation. *Blood*. 2007 Nov 1; 110(9):3463-3471. PMID: 17664354
5. Tichelli A, Gratwohl A. Vascular endothelium as “novel” target of graft-versus-host disease. *Best Pract Res Clin Haematol*. 2008 Jun; 21(2):139-148. PMID: 18503982

TARGETED CANCER THERAPIES

1. Li W, et al. Vascular and metabolic implications of novel targeted cancer therapies: focus on kinase inhibitors. *J Am Coll Cardiol*. 2015 Sep 8; 66(10):1160-1178. PMID: 26337996
2. Moslehi JJ. Cardiovascular toxic effects of targeted cancer therapies. *N Engl J Med*. 2016 Oct 13; 375(15):1457-1467. PMID: 27732808

CARDIOPROTECTION

1. Acar Z, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. *J Am Coll Cardiol*. 2011 Aug 23; 58(9):988-989. PMID: 21851890
2. Akpek M, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. *Eur J Heart Fail*. 2015 Jan; 17(1):81-89. PMID: 25410653
3. Avila MS, et al. Carvedilol for prevention of chemotherapy-related cardiotoxicity: The CECCY trial. *J Am Coll Cardiol*. 2018 May 22; 71(20):2281-2290. PMID: 29540327

4. Boekhout AH, et al. Angiotensin II-receptor inhibition with candesartan to prevent trastuzumab-related cardiotoxic effects in patients with early breast cancer: a randomized clinical trial. *JAMA Oncol.* 2016 Aug 1; 2(8):1030-1037. PMID: 27348762
5. Bosch X, et al. Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (prevention of left ventricular dysfunction with enalapril and carvedilol in patients submitted to intensive chemotherapy for the treatment of malignant hemopathies). *J Am Coll Cardiol.* 2013 Jun 11; 61(23):2355-2362. PMID: 23583763
6. Guglin M, et al. Randomized trial of lisinopril versus carvedilol to prevent trastuzumab cardiotoxicity in patients with breast cancer. *J Am Coll Cardiol.* 2019 Jun 11; 73(22):2859-2868. PMID: 31171092
7. Gulati G, et al. Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2 x 2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. *Eur Heart J.* 2016 Jun 1; 37(21):1671-1680. PMID: 26903532
8. Lynce F, et al. Prospective evaluation of the cardiac safety of HER2-targeted therapies in patients with HER2-positive breast cancer and compromised heart function: the SAFE-HEaRt study. *Breast Cancer Res Treat.* 2019 Jun;175(3):595-603. PMID: 30852761
9. Narayan HK, et al. Dexrazoxane preferentially mitigates doxorubicin cardiotoxicity in female children with sarcoma. *Open Heart.* 2019 Jun 24; 6(1):e001025. PMID: 31297226
10. Nielsen SF, et al. Statin use and reduced cancer-related mortality. *N Engl J Med.* 2012 Nov 8; 367(19):1792-1802. PMID: 23134381
11. Pituskin E, et al. Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101-Breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. *J Clin Oncol.* 2017 Mar 10; 35(8):870-877. PMID: 27893331
12. Seicean S, et al. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline therapy: an observational clinical cohort study. *J Am Coll Cardiol.* 2012 Dec 11; 60(23):2384-2390.
13. Shaikh F, et al. Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-analysis. *J Natl Cancer Inst.* 2015 Nov 23; 108(4). pii:djv357. PMID: 26598513

ADVANCED HEART FAILURE IN CANCER SURVIVORS

1. Bianco CM, et al. Advanced heart failure therapies for cancer therapeutics-related cardiac dysfunction. *Heart Fail Clin.* 2017 Apr; 13(2):327-336. PMID: 28279418
2. Oliveira GH, et al. Characteristics and survival of patients with chemotherapy-induced cardiomyopathy undergoing heart transplantation. *J Heart Lung Transplant.* 2012 Aug; 31(8):805-810. PMID: 22551930

3. Oliveira GH, et al. Increased need for right ventricular support in patients with chemotherapy-induced cardiomyopathy undergoing mechanical circulatory support: outcomes from the INTERMACS Registry (Interagency Registry for Mechanically Assisted Circulatory Support). *J Am Coll Cardiol*. 2014 Jan 28; 63(3):240-248. PMID: 24161324

PERICARDIAL EFFUSION

1. Kaira K, et al. Management of malignant pericardial effusion with instillation of mitomycin C in non-small cell lung cancer. *Jpn J Clin Oncol*. 2005 Feb; 35(2):57-60. PMID: 15709087
2. El Haddad D, et al. Outcomes of cancer patients undergoing percutaneous pericardiocentesis for pericardial effusion. *J Am Coll Cardiol*. 2016 Sep 8; 66(10):1119-1128. PMID: 26337990

CARCINOID HEART DISEASE

1. Davar J, et al. Diagnosing and managing carcinoid heart disease in patients with neuroendocrine tumors: an expert statement. *J Am Coll Cardiol*. 2017 Mar 14; 69(10):1288-1304. PMID: 28279296